Advaxis, Inc. (ADXS) financial statements (2020 and earlier)

Company profile

Business Address 305 COLLEGE ROAD EAST
PRINCETON,, NJ 08540
State of Incorp. DE
Fiscal Year End October 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

1/31/2020
TTM
10/31/2019
10/31/2018
10/31/2017
10/31/2016
10/31/2015
10/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:3432447115211218
Cash and cash equivalents343244241136718
Short-term investments    3946 
Other undisclosed cash, cash equivalents, and short-term investments   47   
Restricted cash and investments  1    
Receivables   4322
Prepaid expense    100
Deferred costs2223411
Other current assets    000
Other undisclosed current assets1133   
Total current assets:3736508116011520
Noncurrent Assets
Operating lease, right-of-use asset5 
Property, plant and equipment4477410
Intangible assets, net (including goodwill)4555433
Intangible assets, net (excluding goodwill)4555433
Other noncurrent assets000000 
Other undisclosed noncurrent assets      0
Total noncurrent assets:1491212953
TOTAL ASSETS:5145629416912023
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities3412141344
Accounts payable0165211
Accrued liabilities33691131
Employee-related liabilities      1
Debt1      
Deferred revenue and credits715  
Other liabilities 000   
Other undisclosed current liabilities0011 00(1)
Total current liabilities:4523212843
Noncurrent Liabilities
Long-term debt and lease obligation6      
Operating lease, liability6 
Liabilities, other than long-term debt 111 00
Other liabilities 111   
Derivative instruments and hedges, liabilities     00
Other undisclosed noncurrent liabilities  141722  
Total noncurrent liabilities:6115192200
Total liabilities:10638395043
Stockholders' equity
Stockholders' equity attributable to parent4240245411911621
Common stock0000000
Treasury stock, value    (0)(0) 
Additional paid in capital434424392355327250108
Accumulated deficit(392)(384)(368)(301)(208)(134)(87)
Total stockholders' equity:4240245411911621
TOTAL LIABILITIES AND EQUITY:5145629416912023

Income statement (P&L) ($ in millions)

1/31/2020
TTM
10/31/2019
10/31/2018
10/31/2017
10/31/2016
10/31/2015
10/31/2014
Revenue, net124 1
Gross profit:1216124 1
Operating expenses(37)(39)(76)(111)(80)(49)(21)
Operating loss:(36)(18)(70)(99)(76)(49)(20)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
(0)(0)(0)(0)(0)(0)0
Interest and debt expense      0
Other undisclosed income (loss) from continuing operations before equity method investments, income taxes(1)141001
Loss from continuing operations before income taxes:(37)(17)(66)(98)(76)(49)(19)
Income tax expense (benefit) (0)(0)4322
Net loss available to common stockholders, diluted:(37)(17)(67)(93)(74)(47)(17)

Comprehensive Income ($ in millions)

1/31/2020
TTM
10/31/2019
10/31/2018
10/31/2017
10/31/2016
10/31/2015
10/31/2014
Net loss:(37)(17)(67)(93)(74)(47)(17)
Comprehensive loss, net of tax, attributable to parent:(37)(17)(67)(93)(74)(47)(17)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: